U.K. cost watchdog rejects Roche, GSK cancer meds

The U.K. hasn't been kind to high-tech cancer drugs this week: The cost-effectiveness watchdog NICE rejected Roche's Herceptin and GlaxoSmithKline's Tykerb for use in breast cancer patients in combination with hormone-blocking drugs; and Roche's Avastin got stiff-armed as a treatment for colorectal cancer that has spread. Article | Report

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.